SUMMER MILLER: Open Payments
NPI 1831829167 · BRANDON, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,099 in 121 payments from 13 companies in 2025. Trend: 2023 $1,665 · 2024 $1,678 · 2025 $2,099
Food & beverage: $2,099
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $345 |
| Lundbeck LLC | 22 | $324 |
| Otsuka America Pharmaceutical, Inc. | 15 | $183 |
| Alkermes, Inc. | 8 | $179 |
| E.R. Squibb & Sons, L.L.C. | 8 | $171 |
| Janssen Pharmaceuticals, Inc | 8 | $151 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $142 |
| Teva Pharmaceuticals USA, Inc. | 7 | $136 |
| Neurocrine BioSciences, Inc. | 7 | $135 |
| Tris Pharma Inc | 7 | $131 |
Products named: VRAYLAR, ABILIFY ASIMTUFII, COBENFY, REXULTI, ARISTADA, INVEGA SUSTENNA, CAPLYTA, INGREZZA.
Industry payments across MS — which companies pay providers there.
